Novo Nordisk to Acquire Akero Therapeutics for Up to $5.2 Billion

Dow Jones – HealthThursday, October 9, 2025 at 10:39:00 AM
PositiveHealth
Novo Nordisk to Acquire Akero Therapeutics for Up to $5.2 Billion
Novo Nordisk's acquisition of Akero Therapeutics for up to $5.2 billion marks a significant move in the pharmaceutical industry. Shareholders of Akero will initially receive $54 per share, with an additional $6 contingent on the approval of the EFX drug by 2031. This deal highlights Novo Nordisk's commitment to expanding its portfolio and investing in innovative treatments, which could lead to advancements in patient care and increased market competitiveness.
— via World Pulse Now AI Editorial System

Was this article worth reading? Share it

Recommended Readings
Novo Nordisk Shareholders Approve New Chair, Board Members
PositiveHealth
Novo Nordisk shareholders have approved the appointment of a new chair and board members. This decision follows pressure from the company's controlling shareholder, who is advocating for changes aimed at revitalizing the company's success in the weight-loss market.